The SMi will be holding its 4th annual conference on Biosimilars and Biobetters on September 24-25, 2012 in London, UK. The conference will offer presentations on the following topics:
• Clinical approach to biosimilar development;
• Development of biosimilar monoclonal antibodies: opportunities and challenges;
• Safety in biosimilar development;
• Panel discussion: Biosimilars vs. biobetters, so which is the better strategy?
• The future of biosimilars in specific emerging markets;
• Minimising patent risk;
• Marketing biosimilars in the EU;
• Global market analysis of follow on biologics;
• Generating a biosuperiors pipeline through Fc engineering: A low-risk approach to improving the performance of therapeutic antibodies;
• Forecasting the future of biosimilars;
• Methods for biobetter development;
• Methods for determining biosimilarity;
• Variations in global regulatory strategy for biosimilars;
• Biosimilars safety: Experience till date;
• Case Study: Biferonex, a biosimilar of interferon beta-1a, and an effective treatment for multiple sclerosis; and
• Innovation in generics: Is it applicable?
A half-day post-conference workshop, entitled "A Critical Review of US and EU Legal Framework for Biosimilar Products Including Practical Examples for Strategic Development," will be offered on September 26, 2012.
The programme for the Biosimilars and Biobetters conference can be found here (Day 1), here (Day 2), and here (workshop). A complete brochure for this conference, including an agenda, description of the sessions, list of speakers, and registration form can be downloaded here.
The registration fee for the conference is £1,399 and for the workshop is £599. Those interested in registering for the conference and workshops can do so here.
Patent Docs is a supporting publication of the Biosimilars and Biobetters conference.
Comments